85 results about "IMMUNE SUPPRESSANTS" patented technology

The invention discloses application of a metal boride nano material in preparation of an immunosuppressant, and belongs to the technical field of biological medicine. Specifically, through a series of researches, it is found that the metal boride nano material catalyzes an organic substrate containing a-CH-OH group in cells, and meanwhile, NAD (P) < + > is converted to generate NAD (P) H, GSH rising is promoted, and cell reductive stress is initiated. The immune cells are further induced to differentiate to an immunosuppressive phenotype, secretion of immunosuppressive factors is promoted, secretion of immune activating factors is inhibited at the same time, and finally the immunosuppressive effect is achieved. The catalytic action of the substance can provide a lasting and stable immunosuppression effect, and the feasibility of the substance in initiation of reduction stress and immunosuppression is proved through in-vivo and in-vitro experiments. The invention provides a new immunosuppression strategy, which is expected to make up the defects of the traditional immunosuppressor, and provides a new choice for related treatment of clinical organ transplantation, autoimmune diseases, inflammatory diseases and the like.

The invention discloses a thiadiazolidinone compound and a preparation method and application thereof, the thiadiazolidinone derivative is a compound with a structure shown as a general formula (I) or pharmaceutically acceptable salt of the compound, and the invention further discloses application of the thiadiazolidinone derivative in medicine for treating PTPN2 / PTPN1 mediated diseases. The compound disclosed by the invention has obvious inhibitory activity on PTPN2 / PTPN1 phosphatase, has important influence on occurrence and development of tumors and immune response, can also be used in combination with an immunosuppressant to treat related immune diseases, can be developed into an anti-tumor drug with high activity, good selectivity and small toxic and side effects, and has the characteristics of strong plasticity and great future modification potential. # imgabs0 #

The present invention relates to combination therapy compositions and methods of combination therapy for the treatment of cancer. The present invention discloses a composition comprising: (i) an effective amount of a programmed cell death protein-1 (PD-1) inhibitor capable of blocking a PD-1 pathway, partially recovering the function of T cells, and enabling these cells to continue killing tumor cells; and (ii) an effective amount of a glucosylceramide synthetase (GCS) inhibitor capable of enhancing the activity of the immune system; wherein the immunosuppressive agent is administered intravenously by using an intravenous dosage form, and the GCS inhibitor is administered orally by using an oral dosage form. The tumor growth can be effectively inhibited by using the composition and the combined treatment method disclosed by the invention.

The present application relates to the technical field of medicine, and specifically includes the application of immunosuppressants in the preparation of drugs for treating pulmonary hypoperfusion type congenital heart disease, and further provides a premature infant pulmonary hypoperfusion animal model, and results show that lung development is significantly improved after using immunosuppressants. The present application verifies the Wnt pathway which is critical for lung development, indicates that immunosuppressants can improve the Wnt pathway changes caused by pulmonary hypoperfusion, confirms that immunosuppressants have a therapeutic effect on the pulmonary hypoperfusion type congenital heart disease caused by pulmonary hypoplasia, provides a new method and idea for improving lung development of such children, and thereby improves the long-term survival quality of congenital heart disease children in China.

This invention belongs to the field of animal model construction technology, specifically relating to a mouse immunosuppressive model that maintains a long-term immunosuppressive state, its construction method, and its application. This invention establishes a stable immunosuppressive state model with reduced neutrophil count and no significant decrease in erythrocyte count by administering different doses of immunosuppressants (10-50 mg / kg body weight) to Balb / c mice via a combination of "reduced total dose + multiple gavage administration + satellite monitoring." The method for constructing this mouse immunosuppressive model reduces drug usage, controls neutrophil count rebound, establishes a stable model of reduced neutrophil count, and avoids deep bone marrow suppression (i.e., does not cause an uncontrollable decrease in erythrocyte or platelet count), which is beneficial for long-term experimental conduct and drug evaluation.